Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Hartmann

Showing results (321-330 of 360) with videos related to

Pageof 36
Sort By:
The British Journal of Dermatology|September 30, 2009
Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trialK Hartmann, F Siebenhaar, B Belloni, et al.
Nanotoxicology|June 13, 2022
Separating toxicity and shading in algal growth inhibition tests of nanomaterials and colored substancesLars Michael Skjolding, Sara Nørgaard Sørensen, Karen Scharling Dyhr, et al.
British Journal of Pharmacology|September 12, 2015
Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptorsA H Sparre-Ulrich, L S Hansen, B Svendsen, et al.
Zeitschrift Fur Gastroenterologie|September 3, 2011
Acute Pancreatitis in a patient with hypercalcemia due to tertiary hyperparathyroidismJ Stephani, A S Akinli, G von Figura, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|February 19, 2022
COVID-19 Lockdown Periods in 2020: Good Maintenance of Metabolic Control in Adults with Type 1 and Type 2 DiabetesB Hartmann, S R Tittel, M Femerling, et al.
Cancer Immunology, Immunotherapy : CII|November 8, 2006
Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteinsMieun Lee, Claudia Kistler, Tanja B Hartmann, et al.
Biochemical Pharmacology|February 27, 2017
GIP(3-30)NH<sub>2</sub> is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin releaseA H Sparre-Ulrich, M N Gabe, L S Gasbjerg, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|December 22, 1998
High levels of serum allopregnanolone in women with premature ovarian failureF Bernardi, B Hartmann, E Casarosa, et al.
Regulatory Peptides|March 21, 2013
Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled studyK B Madsen, C Askov-Hansen, R M Naimi, et al.
Regulatory Peptides|March 19, 2013
A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patientsR M Naimi, K B Madsen, C Askov-Hansen, et al.
Pageof 36

Showing results (321-330 of 360) with videos related to

Sort By:
Pageof 36
The British Journal of Dermatology|September 30, 2009
Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trialK Hartmann, F Siebenhaar, B Belloni, et al.
Nanotoxicology|June 13, 2022
Separating toxicity and shading in algal growth inhibition tests of nanomaterials and colored substancesLars Michael Skjolding, Sara Nørgaard Sørensen, Karen Scharling Dyhr, et al.
British Journal of Pharmacology|September 12, 2015
Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptorsA H Sparre-Ulrich, L S Hansen, B Svendsen, et al.
Zeitschrift Fur Gastroenterologie|September 3, 2011
Acute Pancreatitis in a patient with hypercalcemia due to tertiary hyperparathyroidismJ Stephani, A S Akinli, G von Figura, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|February 19, 2022
COVID-19 Lockdown Periods in 2020: Good Maintenance of Metabolic Control in Adults with Type 1 and Type 2 DiabetesB Hartmann, S R Tittel, M Femerling, et al.
Cancer Immunology, Immunotherapy : CII|November 8, 2006
Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteinsMieun Lee, Claudia Kistler, Tanja B Hartmann, et al.
Biochemical Pharmacology|February 27, 2017
GIP(3-30)NH<sub>2</sub> is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin releaseA H Sparre-Ulrich, M N Gabe, L S Gasbjerg, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|December 22, 1998
High levels of serum allopregnanolone in women with premature ovarian failureF Bernardi, B Hartmann, E Casarosa, et al.
Regulatory Peptides|March 21, 2013
Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled studyK B Madsen, C Askov-Hansen, R M Naimi, et al.
Regulatory Peptides|March 19, 2013
A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patientsR M Naimi, K B Madsen, C Askov-Hansen, et al.
Pageof 36